Table 6.

Treatment-related adverse events.

Adverse events	Any Grade			Grade 3/4
	Combination Group (n = 56)	TACE Group (n = 54)	P value	Combination Group (n = 56)	TACE Group (n = 54)	P value
Treatment-related AEs, n (%)
Hypertension	25 (44.6)	0	<0.001	10 (17.9)	0	0.003
Weight loss	20 (35.7)	8 (14.8)	0.012	3 (5.4)	1 (1.9)	0.637
Diarrhea	17 (30.4)	0	<0.001	2 (3.6)	0	0.492
Appetite decreased	16 (28.6)	2 (3.7)	<0.001	2 (3.6)	0	0.492
Fatigue	20 (35.7)	3 (5.6)	<0.001	2 (3.6)	0	0.492
Rash	7 (12.5)	0	0.022	0	0	–
HFSR	12 (21.4)	0	<0.001	0	0	–
Pruritus	6 (10.7)	0	0.040	0	0	–
Hypothyroidism	5 (8.9)	0	0.074	0	0	–
Gum bleeding	3 (5.4)	0	0.255	0	0	–
Constipation	8 (14.3)	2 (3.7)	0.110	0	0	–
Diabete	2 (3.6)	0	0.492	0	0	–
Biloma	0	2 (3.7)	0.459	0	2 (3.7)	0.459
Arthralgia	3 (5.4)	0	0.255	0	0	–
Hoarseness	4 (7.1)	0	0.136	0	0	–
laboratory-related AEs, n (%)
Proteinuria	10 (17.9)	0	0.003	0	0	–
Decreased WBC	20 (35.7)	7 (13.3)	0.006	3 (5.4)	1 (1.9)	0.637
Decreased PLT	23 (41.1)	12 (22.2)	0.034	3 (5.4)	1 (1.9)	0.637
Elevated TB	9 (16.1)	12 (22.2)	0.412	1 (1.8)	2 (3.7)	0.975
Decreased ALB	25 (44.6)	21 (38.9)	0.541	2 (3.6)	2 (3.7)	1.000
Elevated ALT	16 (28.6)	20 (37.0)	0.344	1 (1.8)	3 (5.6)	0.585
Elevated AST	19 (33.9)	24 (44.4)	0.258	1 (1.8)	3 (5.6)	0.585
Elevated GGT	15 (26.8)	20 (37.0)	0.249	0	3 (5.6)	0.229
Elevated Cr	2 (3.6)	0	0.492	0	0	–

p-value was calculated by a two-sided Chi-square test.

HFSR, hand-foot skin reaction; WBC, white blood cell; PLT, platelet; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; Cr, creatinine.